Overview of Sales, Earnings and Financial Position
Favorable study results for rivaroxaban
Bayer Links
News
Favorable study results for rivaroxaban
Leverkusen. Rivaroxaban, a novel, once-daily direct Factor Xa inhibitor in tablet form for the prevention and treatment of blood clots, has been shown in a Phase III study to be more effective than the current therapeutic standard enoxaparin in preventing venous thromboembolism (VTE) after knee replacement surgery. In this study, patients treated with rivaroxaban were 49 percent less likely to suffer deep-vein thrombosis (DVT), pulmonary embolism or death than those treated with enoxaparin. There was an even greater reduction (62%) in the risk of developing major VTE. Rivaroxaban also demonstrated a similarly low rate of major bleeding compared to enoxaparin. As an oral treatment, rivaroxaban would allow convenient administration in the hospital and at home.
The active ingredient rivaroxaban is currently undergoing advanced clinical testing in the prevention and treatment of acute and chronic thrombosis. It is being co-developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development. It is intended to submit a regulatory filing for the prevention of VTE in orthopedic surgery by the end of 2007 in Europe and in 2008 in the United States.
The active ingredient rivaroxaban is currently undergoing advanced clinical testing in the prevention and treatment of acute and chronic thrombosis. It is being co-developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development. It is intended to submit a regulatory filing for the prevention of VTE in orthopedic surgery by the end of 2007 in Europe and in 2008 in the United States.
Bookmark this page
E-mail this page
Advanced Search
